Healthcare Industry News:  Diamics 

Diagnostics Oncology Personnel

 News Release - April 24, 2007

Diamics Names Mitchell Golbus, MD, as Chief Medical and Technical Officer

Professor Emeritus OB/GYN at UCSF, Dr. Golbus Brings Significant Clinical and Molecular Diagnostic Experience

NOVATO, Calif., April 24 (HSMN NewsFeed) -- Diamics, Inc., a privately-held company developing products for cancer screening and diagnostics, has named Mitchell Golbus, MD, to the position of Chief Medical and Technical Officer. Dr. Golbus is a Professor Emeritus of Obstetrics and Pediatrics at the University of California, San Francisco. Dr. Golbus will be responsible for all medical aspects for Diamics including the medical advisory board and clinical trials and will direct the final development of the molecular-based cervical screening system for the company.

"We are delighted to welcome Dr. Golbus to Diamics and are confident that his extensive background and track record of success in diagnostic innovation will help the company achieve its goals," said Peter Gombrich, CEO and Chairman of Diamics. "Mitchell's reputation in the field in addition to his extensive business experience in the development of innovative products will be of great value to Diamics as we move ahead with our worldwide clinical trials. In addition, because of his experience in genetics, he will drive the next-generation advances in molecular-based systems being undertaken by the company. We are very fortunate to be able to attract someone of his caliber as part of the Diamics team."

"I am excited about joining such a strong management team and working on Diamics' technology that combines molecular markers with cervical mapping to offer a simple yet sophisticated approach to cervical cancer screening," said Dr. Golbus. "I am looking forward to leading the medical developments that will allow the Diamics' technology to be easily adapted as a point of care test to help expand cervical cancer screening worldwide."

Dr. Golbus is Board Certified in both Obstetrics/Gynecology and Medical Genetics. He received his degree in medicine from the University of Illinois in 1963. He completed his residency, was a research fellow and became Professor at UCSF in 1981. He has held the position as Professor Emeritus since 1994. While at UCSF he founded several diagnostic companies specifically dealing with genetic karyotyping. Between 1994 and 1998 he was a consultant to Applied Imaging (Santa Clara, CA) on research to develop a prenatal test using fetal cellular material in the maternal circulation. From 1999 to present he has participated in medical missions to Guatemala. He has published over 240 peer-reviewed articles, has written 60 book chapters and has had over 120 accepted and published abstracts.

Diamics recently received FDA 510(k) clearance for its innovative CerCol(TM) collector for collection of cervical cytology material and its transfer for Pap analysis. The Beijing Jingmin Hospital Group recently awarded the Company a contract to provide the CerCol(TM) collectors and Diamics' next generation molecular-based automated cervical cancer screening systems to the hospital group.

About Diamics, Inc.

Diamics, Inc. is a privately owned medical device and diagnostics company located in the San Francisco Bay Area. The company is committed to developing, manufacturing, and marketing cost effective, molecular-based cancer screening and diagnostic systems that will increase long-term cancer survival rates through early detection. Diamics' management team has an extensive track record of success in the medical device and diagnostics industries. The company's mission is twofold: to help medical personnel worldwide improve the lives of the people they treat and to generate a return on investment for its shareholders. For more information, please visit

Source: Diamics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.